Product category:
Laboratory and scientific training and education
News Release from: Cisbio International | Subject: HTRF In Drug Discovery
Edited by the Laboratorytalk Editorial
Team on 11 July 2007
Third symposium on HTRF in drug
discovery
Cisbio international, a developer of HTRF technology for assay development and drug screening, says its third HTRF in Drug Discovery Symposium will be held 26-28 September 2007 in Sonoma, California
The three-day event will assemble experts in compound screening and lead optimisation, therapeutic area leaders, scientists and R+D managers from the pharmaceutical and biotechnology industries to discuss HTRF technology and its applications in the fields of drug screening, target discovery and mechanistic HTRF (homogenous time-resolved fluorescence) is Cisbio's proprietary, highly sensitive, robust technology for the detection of molecular interactions and is widely used for the high throughput stage of drug development
This article was originally published on Laboratorytalk on 10 May 2005 at 8.00am (UK)
Related stories
First blood test for mesothelioma
Up until now, there have been no reliable serum tumour markers for mesothelioma, which means that diagnosis, screening and monitoring responses to treatment have been difficult
Assay development for GPCR-Gq screening
Homogeneous screening platform delivers precise and time-sensitive second messenger measurement, and also represents a novel functional means of precisely investigating GPCR mechanistics
As part of its ongoing commitment to providing the highest quality technical support to HTRF customers, Cisbio established its annual symposium in 2005 as a forum for exchanging ideas on drug screening and the latest in HTRF innovation.
The conference will open with a keynote speech addressing groundbreaking developments in screening methodologies.
Six in-depth scientific sessions will be held with drug discovery experts who use HTRF, to address how this technology improves all research phases for new active molecules, in particular when applied to the fields of GPCR and kinase screening.
Cisbio has developed a comprehensive HTRF technology platform for these areas; the IP-One and cAMP assays for GPCR screening and the HTRF Kinease platform and HTRF toolbox reagents for kinase screening and profiling will be featured.
Two sessions will also be dedicated to using HTRF as an alternative to conventional technologies and to the study of the ubiquitination pathway.
Speakers include: Haim Barr, Proteologics; Ulf Bomer, Bayer Schering; Rochdi Bouhelal, Novartis; Achim Brinker, GNF; Jennifer Brogdon, Novartis; Neil Burford, BMS; Scott Feighner, Merck; Ralph Garripa, Hoffmann-La-Roche; Marcie Glicksman, Harvard Medical School; Michael Jobling, AstraZeneca; Eric Johnson, Abbott; James Pai, Schering Plough; Jean-Philippe Pin, IGF; Jean-Christophe Rain, Hybrigenics; Tim Spicer, Scripps Institute; D Williams, Medarex; Wei Zhang, NIH Roadmap.
Cisbio collaborates with research laboratories from around the globe, and has embarked upon a number of partnerships and customer-based programs where HTRF is currently deployed.
The symposium will also offer HTRF users an opportunity to network with other HTRF users, drug screening experts and consult on-site with Cisbio's scientific team. Request a free brochure from Cisbio International ...
• Cisbio International: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
